Managing GIST in the imatinib era: optimization of adjuvant therapy.

about

Receptor tyrosine kinases: Characterisation, mechanism of action and therapeutic interests for bone cancers Current status of immunotherapy for gastrointestinal stromal tumor.

P2860

Q28082793-4FD7FE64-2170-4EE6-80D1-98E7265A13DB Q39130013-E91147C9-2FDD-4F43-8D86-EEFC0408BC33

P2860

Managing GIST in the imatinib era: optimization of adjuvant therapy.

Item

http://www.wikidata.org/entity/Q38262193

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

2014年學術文章

@zh

2014年學術文章

@zh-hant

name

Managing GIST in the imatinib era: optimization of adjuvant therapy.

@en

type

Item

label

Managing GIST in the imatinib era: optimization of adjuvant therapy.

@en

prefLabel

Managing GIST in the imatinib era: optimization of adjuvant therapy.

@en

P1476

Managing GIST in the imatinib era: optimization of adjuvant therapy.

@en

P2093

Jonathan C Trent

http://www.w3.org/2001/XMLSchema#string

Meenakshi P Subramanian

http://www.w3.org/2001/XMLSchema#string

P2860

Combined surgical and molecular therapy: the gastrointestinal stromal tumor model

Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors.

Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor.

KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours.

Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

A two-arm phase II study of temozolomide in patients with advanced gastrointestinal stromal tumors and other soft tissue sarcomas.

Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: the ACOSOG Z9001 trial.

Long-term results of adjuvant imatinib mesylate in localized, high-risk, primary gastrointestinal stromal tumor: ACOSOG Z9000 (Alliance) intergroup phase 2 trial

Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients.

P304

1445-1459

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/14737140.2014.952284

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2014-10-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25340579

http://www.w3.org/2001/XMLSchema#string

Managing GIST in the imatinib era: optimization of adjuvant therapy.

about

P2860

P2860

Managing GIST in the imatinib era: optimization of adjuvant therapy.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698